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Association of antiretroviral therapy with high-risk human 
papillomavirus, cervical intraepithelial neoplasia, and 
invasive cervical cancer in women living with HIV: 
a systematic review and meta-analysis
Helen Kelly, Helen A Weiss, Yolanda Benavente, Silvia de Sanjose, Philippe Mayaud, for the ART and HPV Review Group*
Summary
Background The interactions between antiretroviral therapy (ART) and high-risk human papillomavirus (HPV) and 
cervical lesions in women living with HIV are poorly understood. We reviewed the association of ART with these 
outcomes.
Methods We did a systematic review and meta-analysis by searching MEDLINE and Embase databases for cross-
sectional or cohort studies published in English between Jan 1, 1996, and May 6, 2017, which reported the association 
of ART with prevalence of high-risk HPV or prevalence, incidence, progression, or regression of histological or 
cytological cervical abnormalities, or incidence of invasive cervcal cancer. Studies were eligible if they reported the 
association of combination ART or highly active ART use with the following outcomes: high-risk HPV prevalence; 
squamous intraepithelial lesion (SIL) or cervical intraepithelial neoplasia (CIN) prevalence, incidence, progression, or 
regression; and invasive cervical cancer incidence among women living with HIV. We did random-effects meta-
analyses to estimate summary statistics. We examined heterogeneity with the I² statistic. This review is registered on 
the PROSPERO database at the Centre of Reviews and Dissemination, University of York, York, UK (registration 
number CRD42016039546).
Findings We identified 31 studies of the association of ART with prevalence of high-risk HPV (6537 women living with 
HIV) and  high grade cervical lesions (HSIL-CIN2+; 9288 women living with HIV). Women living with HIV on ART 
had lower prevalence of high-risk HPV than did those not on ART (adjusted odds ratio [aOR] 0·83, 95% CI 0·70–0·99; 
I²=51%, adjusted for CD4 cell count and ART duration), and there was some evidence of association with HSIL-CIN2+ 
(0·65, 0·40–1·06; I²=30%). 17 studies reported the association of ART with longitudinal cervical lesion outcomes. 
ART was associated with a decreased risk of HSIL-CIN2+ incidence among 1830 women living with HIV 
(0·59, 0·40–0·87; I²=0%), SIL progression among 6212 women living with HIV (adjusted hazard ratio [aHR] 0·64, 
95% CI 0·54–0·75; I²=18%), and increased likelihood of SIL or CIN regression among 5261 women living with HIV 
(1·54, 1·30–1·82; I²=0%). In three studies among 15 846 women living with HIV, ART was associated with a reduction 
in invasive cervical cancer incidence (crude HR 0·40, 95% CI 0·18–0·87, I²=33%).
Interpretation Early ART initiation and sustained adherence is likely to reduce incidence and progression of SIL and 
CIN and ultimately incidence of invasive cervical cancer. Future cohort studies should aim to confirm this possible 
effect.
Funding UK Medical Research Council. 
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Cervical cancer is the most common cancer affecting 
women in low-income and middle-income countries,1 
and one of the most common cancers in women living 
with HIV.2 Women living with HIV have higher 
prevalence of genital high-risk oncogenic human 
papillomavirus (HPV) infection than do the general 
population,3 they are also more likely to have persistent 
infection4 and progression of cervical intraepithelial 
neoplasia (CIN) lesions.5 As combined antiretroviral 
therapy (ART) is scaled up, the effect on cervical cancer 
due to longer survival is unknown.
The interactions of ART and the natural history of 
high-risk HPV and cervical lesions in women living with 
HIV are poorly understood. Observational studies differ 
with respect to study design, outcomes, timing of ART 
initiation and effectiveness of ART use, making it 
difficult to estimate the true effect of ART. Previous 
systematic reviews have explored the association of ART 
and high-risk HPV and cervical lesions,5–7 but to our 
knowledge no meta-analysis has quantified the risk of 
high-risk HPV infection and cervical lesions among ART 
users compared with ART-naive women. In view of the 
large and increasing number of women on ART, 
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improved understanding of the interplay of ART, 
immune recovery, and virological control on the natural 
history of high-risk HPV infection and CIN progression 
is needed to guide screening programmes.
We aimed to review and to summarise the literature 
about the association of ART with high-risk HPV 
prevalence, and with cervical lesion prevalence, incidence, 
progression and regression, and invasive cervical cancer 
incidence. We also aimed to investigate the role of HIV-
related cofactors that might modify these associations, 
such as ART duration, timing of treatment initiation, 
immune suppression, and recovery.
Methods
Search strategy and selection criteria
We searched MEDLINE and Embase databases for pub-
lications in English with search terms for human 
papillomavirus, CIN, SIL, invasive cervical cancer, and 
ART (appendix p 1). Reference lists of review articles and 
all articles identified in the systematic search were 
checked. We did the search from Jan 1, 1996 (when highly 
active ART came into use), up to May 6, 2017. One author 
(HK) screened all abstracts. Two authors (HK and PM) 
obtained full-text copies of relevant publications, assessed 
them for eligibility, and reached consensus on potential 
relevance.
Studies were eligible if they reported the association 
of combination ART or highly active ART use (referred 
to as ART from now on) with the following outcomes: 
prevalence of high-risk HPV; prevalence, incidence, 
progression, or regression of SIL diagnosed with 
cytology or CIN diagnosed with histology; and incidence 
of invasive cervical cancer among women living with 
HIV. We also considered studies eligible if they 
See Online for appendix
Research in context
Evidence before this study
Women living with HIV have higher prevalence of genital 
high-risk oncogenic human papillomavirus (HPV) infection 
than the general population and are more likely to have 
persistent infection and progression of cervical intraepithelial 
neoplasia (CIN) lesions. Increased access to antiretroviral 
therapy (ART) has increased the life expectancy of women 
living with HIV, but many remain susceptible to high-risk HPV 
incidence and persistence and cervical lesion incidence and 
progression. The precise effect of ART on the natural history of 
high-risk HPV infection and cervical lesion progression is not 
well established, and studies evaluating this association have 
reported conflicting results. We searched all available 
publications in English in the MEDLINE and Embase databases 
from Jan 1, 1996, to May 6, 2017, which reported the 
association of ART with prevalence of high-risk HPV or 
prevalence, incidence, progression, or regression of histological 
(CIN) or cytological (squamous intraepithelial lesions [SIL]) 
cervical abnormalities, or incidence of invasive cervical cancer. 
We found 31 studies of the association of ART with prevalence 
of high-risk HPV (6537 women living with HIV), and CIN of 
grade 2 or higher (CIN2+) diagnosed by histology or high-grade 
SIL (HSIL+) diagnosed by cytology only (9288 women living 
with HIV). Furthermore, 17 studies reported the association of 
ART with longitudinal cervical lesion outcomes (any CIN or SIL), 
providing data for 6864 women living with HIV, and three 
studies reported the association of ART with incidence of 
invasive cervical cancer among 15 826 women living with HIV.
Added value of this study
We found that prevalence of high-risk HPV and histology 
diagnosed  HSIL-CIN2+ was lower among ART users compared 
with those not on treatment. ART was associated with a 
decreased risk of histology diagnosed HSIL-CIN2+ incidence, 
cytology diagnosed SIL incidence, and SIL progression. Women 
living with HIV on ART had an increased likelihood of histology 
diagnosed CIN or cytology diagnosed SIL regression and a 
decreased risk of invasive cervical cancer incidence. To our 
knowledge, this is the first study to quantify the effect of ART on 
prevalent high-risk HPV, high-grade cervical lesion outcomes, and 
invasive cervical cancer in a meta-analysis. Studies that adjusted 
for either nadir or current CD4 cell count and time-varying effects 
of ART were more likely to show a protective effect of ART on 
these outcomes. Studies from Africa and Europe or 
North America provide indication that ART was associated with 
lower prevalence of high-risk HPV and cervical lesions, and over 
prolonged duration, ART can prevent cervical lesion incidence 
and progression, promote regression, and prevent incidence of 
invasive cervical cancer. Fewer studies exist from Asia and 
Latin America with the majority being cross-sectional in design, 
and these studies were less likely to report any protective 
association of ART. Because some studies from Latin America 
have reported an increased risk of high-risk HPV and CIN2+ 
among women with a lower nadir CD4 cell count, the lack of 
association might reflect the timing of ART in relation to HPV 
infection and cervical lesion development in these populations. 
Our findings highlight the importance of early ART initiation 
(before reaching a low nadir CD4 cell count) and sustained 
effectiveness, as evidenced by duration, high adherence, 
virological control, and CD4 cell recovery, in controlling HPV 
infection and cervical disease progression.
Implications of all the available evidence
The current recommendation of encouraging earlier ART 
initiation, coupled with rapid virological control, and sustained 
adherence is likely to lead to an earlier and possibly more 
functionally complete mucosal immune reconstitution. ART 
users with low or unknown nadir CD4 cell count should be 
screened frequently because their risk of high-risk HPV 
infection and cervical lesion progression remains high. 
Longitudinal studies in the era of immediate unconditional ART 
initiation should capture the greater benefit of ART treatment 
on cervical disease and cancer.
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provided raw data to calculate an unadjusted effect 
estimate.
For high-risk HPV outcomes, we included studies 
reporting genital high-risk HPV. There were no ex-
clusions on HPV test methods. For the prevalent lesion 
outcomes, studies reporting cervical lesions using visual 
inspection with acetic acid or Lugol’s iodine but without 
high-resolution colposcopy were excluded because of the 
poor sensitivity and specificity of visual inspection alone 
in detecting high-grade lesions.
For prevalent outcomes, cross-sectional studies were 
included if they reported the association of ART use with 
high-risk HPV or any grade of histological or cytological 
cervical lesion. Cohort studies were included if partici-
pants initiated ART at enrolment, were followed up, and 
had measures of high-risk HPV at baseline and in the 
follow-up visit.
For the longitudinal outcomes, we included cohort 
studies reporting the association of ART with the inci-
dence, progression, and regression of any CIN grade 
diagnosed by histology or any SIL grade diagnosed by 
cytology (which could include atypical squamous cells of 
undetermined significance as well as low-grade and high-
grade lesions) because SIL represent various incremental 
degrees of high-risk HPV persistence and subsequent 
lesion development. Only cohort studies examining 
invasive cervical cancer incidence among ART users and 
treatment-naive women in the ART era were included 
because they provide the most robust direct comparison 
of the effect of therapy on invasive cervical cancer.
For publications that reported results from the same 
cohort, but at different follow-up visits, the publication 
that gave the most relevant description of the cohort and 
study design and the most complete set of results was 
included. There was no restriction on age or geographical 
location.
Data extraction
From the consensus list, one author (HK) extracted the 
data and a second author (HAW) checked a random 
sample of 25%. For studies reporting prevalence of 
high-risk HPV or cervical lesions, odds ratios (ORs) were 
extracted. For studies reporting cervical lesion incidence, 
progression or regression, hazard ratios (HRs) or ORs 
were extracted.
Methodological quality assessment
We assessed studies primarily on adjustment for 
HIV-related factors (current and nadir CD4 cell count 
and ART duration). We considered cross-sectional 
studies that adjusted for either current or nadir CD4 cell 
count or ART duration separately in sensitivity analyses, 
as were cohort studies that adjusted for time on ART 
during follow-up. We also assessed study quality by 
participant selection, statistical method, HPV test 
used, and cervical lesion (cytological or histological) 
classi fication (appendix pp 6–18).
Statistical analysis
We did meta-analyses for the discrete outcomes of 
high-risk HPV prevalence, high-grade lesion (high-grade 
squamous intraepithelial lesion or cervical intraepithelial 
neoplasia grade 2 or higher, diagnosed by cytology or 
histology [HSIL-CIN2+]) prevalence, incidence, pro-
gression and regression of any histology diagnosed CIN 
or cytology diagnosed SIL, and incidence of invasive 
cervical cancer.
We report adjusted effect estimates when available. For 
the cross-sectional studies in which adjusted effect 
estimates were not reported but raw data were provided, 
we calculated crude ORs (HK) and independently verified 
them (HAW and PM). We contacted authors when the 
paper suggested that relevant data were collected but not 
reported.
We used random-effects meta-analysis to estimate 
pooled effects to account for between-study heterogeneity.8 
We examined heterogeneity using the I² statistic and 
publication bias using funnel plots and Begg’s test for 
correlation between the effect estimate and their 
variances.9,10 We did an influence analysis to assess the 
robustness of the pooled summary effects by excluding 
each of the studies from the pooled estimate. We did 
subgroup analyses by geographical region to compare 
pooled effects and heterogeneity. We did sensitivity 
analyses excluding studies unadjusted for HIV-related 
factors. We analysed data using Stata version 14.
This review is reported according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA)11 and the Meta-analysis Of Observational 
Studies in Epidemiology (MOOSE) guidelines.12 The 
review protocol and the dataset are available online.
Role of the funding source
There was no funding source for this study. The 
corresponding author had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
We identified 605 publications for the association of ART 
and high-risk HPV prevalence through MEDLINE and 
Embase searches, 198 of which were duplicates 
and removed; and we excluded 343 after abstract 
review, leaving 64 articles for full-text review. Finally, 
16 articles matched inclusion criteria and we identified 
three additional publications through cross-referencing 
(figure 1). Data were extracted from 19 publications 
(12 cross-sectional; seven cohort) representing 20 discrete 
populations and providing data from 6537 women living 
with HIV, of whom 3677 (56%) were taking ART (range 
19–85% in cross-sectional studies), 2032 (31%) were 
ART-naive, and 828 (13%) were ART initiators. 
Four studies13–16 compared high-risk HPV before and 
after ART initiation (ie, women acted as their own 
controls; table 1; appendix p 2). One publication provided 
For the protocol see 
https://www.crd.york.ac.uk/
PROSPERO/display_record.
asp?ID=CRD42016039546.
For the dataset see http://dx.doi.
org/10.17632/cg8k3d7rc8.1
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data from two countries,17 and was considered as 
two individual studies in the analysis, resulting in 
20 included studies.
The pooled OR among 20 studies13–31 indicates that 
women living with HIV on ART had a lower risk of 
high-risk HPV prevalence compared with women who 
were ART-naive (crude OR 0·82, 95% CI 0·68–0·98); but 
there was a high degree of heterogeneity between studies 
(I²=71%, p value for heterogeneity<0·0001; table 2, 
figure 2). Restricting the analysis to the 12 studies that 
adjusted for either current or nadir CD4 cell count, or 
ART duration,13,15–17,19–21,24,25,29,30 the OR was similar but with a 
moderate degree of heterogeneity (adjusted [a] OR 0·85, 
95% CI 0·73–1·00, adjusted for nadir or current CD4 cell 
count; aOR 0·83, 95% CI 0·70–0·99, I²=51%, p value for 
heterogeneity=0·02, with additional adjustment for 
duration on ART). The reduction in heterogeneity on 
adjustment for confounding was most noticeable among 
the studies from Africa; among six studies13,17,19–21 the aOR 
was 0·70 (95% CI 0·56–0·88) with no evidence of 
hetero geneity (I²=0·0%, p=0·97). Similarly, among 
studies from Europe or North America, three studies15,16,30] 
showed a similar reduction in high-risk HPV (aOR 0·74, 
95% CI 0·59–0·93; I²=48%, p=0·14). This was by contrast 
605 records identified through 
database searching 
407 records after duplicates removed
407 records screened
64 full-text articles assessed for
eligibility
343 records excluded
3 records identified through
cross-referencing
48 full-text articles excluded
18 had no ART stratification
7 not high-risk HPV
5 genotype specific analysis
3 longitudinal high-risk HPV
7 results from same cohort at
different timepoint
4 enrolled <50 participants
2 modelling study
1 combined cervical or anal 
HPV
1 had no stratification by 
gender
19 studies included in qualitative 
synthesis
19 studies included in quantitative 
synthesis (meta-analysis)
A B
1158 records identified through 
database searching
1031 records after duplicates 
removed
1031 records screened
142 full-text articles assessed
for eligibility
889 records excluded
104 full-text articles excluded
46 had no ART stratification
21 CIN treatment outcomes
20 pre-HAART versus 
post-HAART era studies
7 were same cohort at 
different timepoint
6 no effect estimate given 
and no raw data and no 
reference group
4 enrolled <50 participants
10 records identified through
cross-referencing
48 studies included in qualitative
synthesis*
13 prevalence (HSIL-CIN2+)
12 prevalence (ASCUS+/LSIL+/
CIN1+/VI)
12 incidence (CIN2+/SIL)
10 progression (SIL)
10 regression(CIN/SIL)
3 invasive cervical cancer 
incidence
33 studies included in quantitative
synthesis (meta-analysis)*
13 prevalence (HSIL–CIN2+)
12 incidence (CIN2+/SIL)
      6 progression (SIL)
      6 regression (CIN/SIL)
      2 invasive cervical cancer 
      incidence
Figure 1: Study selection for outcomes of high-risk HPV (A) and cervical lesions (B)
HPV=human papillomavirus. HAART=highly active antiretroviral therapy. CIN=cervical intraepithelial neoplasia. SIL=squamous intraepithelial lesions. 
HSIL=high-grade SIL. LSIL=low-grade SIL. ASCUS= atypical squamous cells of undetermined significance. *Some studies contributed to more than one outcome 
(ie, incidence and progression, or progression and regression). Individual studies are summarised in table 1.
Articles
www.thelancet.com/hiv   Vol 5   January 2018 e49
Location Study period Total 
sample
Mean or median 
age (IQR), years
ART users (%) Cervical lesions
Definition Diagnostic method
High risk HPV prevalence
Zeier et al (2015)13 Western Cape, South Africa 2009–11 300 36 (ART); 
31 (ART-naive)
68% initiated during 
follow-up*
·· ··
Rositch et al (2013)14 Rakai, Uganda 2007–10 96 35 (31–44) 0%* ·· ··
Minkoff et al (2010)15 5 cities, USA 1994–2002 286 NR 0%* ·· ··
Fife et al (2009)16 Puerto Rico/USA 2001–05 146 35 0%* ·· ··
Kelly et al (2017)17 Ouagadougou, Burkina Faso 2011–12 570 36 (31–41) 67% ·· ··
Kelly et al (2017)17 Johannesburg, South Africa 2011–12 613 34 (30–40) 65% ·· ··
Ezechi et al (2014)18 Ogun and Lagos, Nigeria NR 220 37 (31–45) 72% ·· ··
Reddy et al (2014)19 Lilongwe, Malawi 2011–12 294 36 (30–43) 85% ·· ··
De Vuyst et al (2012)20 Nairobi, Kenya 2009 497 38 75% ·· ··
Jaquet et al (2012)21 Abidjan, Côte d’Ivoire Jun to Oct, 2010 254 36 (32–42) 75% ·· ··
Veldhuijzen et al (2011)22 Kigali, Rwanda 2006–09 124 27 (23–32) 40% ·· ··
Menezes et al (2016)23 Chennai, India July to Aug, 
2011
50 33 48% ·· ··
Zhang et al (2014)24 Yunnan, China NR 301 34 64% ·· ··
Mane et al (2012)25 Pune, India NR 277 33 56% ·· ··
Aggarwal et al (2012)26 Chandigarh, India NR 130 34 75% ·· ··
Rocha-Brischiliari et al (2014)27 Maringa city, Brazil Apr to Oct, 2011 178 Range: 
18–66 years
79% ·· ··
Dames et al (2014)28 Nassau, Bahamas Feb to Sep, 
2008
165 40 81% ·· ··
Grinsztejn et al (2009)29 Rio de Janeiro, Brazil 1996–2006 634 36 (29–43) 68% ·· ··
Konopnicki et al (2013)30 Brussels, Belgium 2002–11 652 38 (31–45) 79% ·· ··
Blitz et al (2013)31 11 cities, Canada 1993–2002 750 33 (28–38) 19% ·· ··
HSIL-CIN2+ prevalence
Kelly et al (2017)17 Ouagadougou, Burkina Faso 2011–12 530 36 (31–41) 73% HSIL-CIN2+ Histology
Kelly et al (2017)17 Johannesburg, South Africa 2011–12 566 34 (30–40) 65% HSIL-CIN2+ Histology
De Vuyst et al (2012)20 Nairobi, Kenya 2009 470 38 75% HSIL-CIN2+ Histology
Memiah et al (2015)32 Kiambu, Kenya 2009–10 686 52% <40 years 16% HSIL-CIN2+ Histology
Huchko et al (2014)33 Kisumu, Kenya 2007–10 3185 33 (29–39) 50% HSIL-CIN2+ Histology
Mabeya et al (2012)34 Eldoret, Kenya NR 149 34 67% HSIL-CIN2+ Histology
Ezechi et al (2014)35 Ogun and Lagos, Nigeria NR 490 37 (31–45) 76% HSIL-CIN2+ Cytology
Firnhaber et al (2010)36 Johannesburg, South Africa NR 1010 34 (18–65) 65% HSIL-CIN2+ Cytology
Mogtomo et al (2009)37 Douala, Cameroon NR 70 35 50% HSIL-CIN2+ Cytology
Feng et al (2017)† Yunnan, China 2009 301 34 64% HSIL-CIN2+ Histology
Sahasrabuddhe et al (2010)38 Pune, India 2006–07 271 30 (27–34) 26% HSIL-CIN2+ Histology
De Andrade et al (2011)39 Rio de Janeiro, Brazil 1996–2007 340 34 (28–41) 26% HSIL-CIN2+ Histology
Patrelli et al (2013)40 Parma, Italy 1993–2010 194 41 66% HSIL-CIN2+ Cytology
Kitchener et al (2007)41 6 cities, Europe 2000–04 1026 33 56–79% HSIL-CIN2+ Cytology
SIL-CIN incidence
Minkoff et al (2010)15 5 cities, USA 1994–2002 286 NR All ART initiators Normal to ASCUS+ Cytology
Kelly et al (2017)17 Johannesburg, South Africa 2011–12 379 34 (30–40) 71% at end of follow-up <CIN2 to CIN2/3 Histology
Adler et al (2012)54 Soweto, South Africa 2003–10 767 33 2% at baseline; 17% 
initiation during 
follow-up
Normal to ASCUS Cytology
Firnhaber et al (2012)55 Johannesburg, South Africa NR 326 35 (31–41) 71% at baseline Normal to ASCUS+ Cytology
Kreitchmann et al (2013)56 Porto Alegre, Brazil 1997–2007 349 32 38% <LSIL to LSIL+, Cytology
Sirera et al (2008)57 Barcelona, Spain 1997–2006 127 35 71% at baseline Normal to LSIL+ Cytology
Soncini et al (2007)58 Parma, Italy 1993–2003 101 NR 43% through follow-up Normal to LSIL+ Cytology
Lehtovirta et al (2006)59 Helsinki, Finland 1989–2003 55 30–36 48% at baseline; 64% at 
follow-up
Normal to LSIL+ Cytology
(Table 1 continues on next page)
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Location Study period Total 
sample
Mean or median 
age (IQR), years
ART users (%) Cervical lesions
Definition Diagnostic method
(Continued from previous page)
Heard et al (2006)60 Paris, France 1993–2005 298 33 (29–38) 49% through follow-up Normal to ASCUS+ Cytology
Schuman et al (2003)61 4 cities, USA 1993–95 629 35 33% at baseline Normal to LSIL+ Cytology
Ellerbrock et al (2000)62 New York, USA 1991–96 328 47% <35 years 54% on ≥1 ARV during 
study period
Normal to ASCUS+ Cytology
Clifford et al (2016)63 5 cities, Switzerland 1995–2013 1451 NR 54% <CIN2 to CIN2/3 Histology
SIL progression
Blitz et al (2013)31 11 cities, Canada 1993–2002 326 33 (28–38) 19% at baseline; 64% by 
study end
ASCUS to any grade higher Cytology
Adler et al (2012)54 Soweto, South Africa 2003–10 1123 33 2% at baseline; 17% 
initiation during 
follow-up
Subsequent smear with 
worsening dysplasia
Cytology
Firnhaber et al (2012)55 Johannesburg, South Africa NR 326 35 (31–41) 71% at baseline Normal to LSIL+; LSIL to 
HSIL+
Cytology
Schuman et al (2003)61 4 cities, USA 1993–95 629 35 33% at baseline Normal/ASCUS to LSIL+; LSIL 
to HSIL
Cytology
Zeier et al (2012)64 Western Cape, South Africa 2004–09 1048 33 18% LSIL to HSIL+ Cytology
Omar et al (2011)65 Soweto, South Africa 2003–10 1074 32 (28–37) 6% at baseline; 20% 
initiated during 
follow-up
Normal to LSIL+; LSIL to 
HSIL+/ASC-H
Cytology
Kim et al (2013)66 New York, USA 1991–2011 245 37 NR Normal to ASCUS+; ASCUS to 
LSIL+
Cytology
Paramsothy et al (2009)67 4 cities, USA 1996–2000 537 34 47% during follow-up Normal to ASCUS; ASCUS to 
LSIL; LSIL to HSIL
Cytology
Minkoff et al (2001)68 6 cities, USA 1994–95 741 37 1% at baseline Subsequent smear any grade 
higher than baseline
Cytology
Lillo et al (2001)69 Milan, Italy 1995–97 163 34 46% through follow-up Normal to LSIL+; LSIL to HSIL Cytology
SIL or CIN regression
Minkoff et al (2010)15 5 cities, USA 1994–2002 286 NR All ART initiators SIL to lower grade Cytology
Blitz et al (2013)31 11 cities, Canada 1993–2002 326 33 (28–38) 19% at baseline; 64% by 
study end
≥ASCUS to <ASCUS Cytology
Adler et al (2012)54 Soweto, South Africa 2003–10 1123 33 2% at baseline; 17% 
initiation during follow-
up
Subsequent improvement in 
cytological results
Cytology
Schuman et al (2003)61 4 cities, USA 1993–95 629 35 33% at baseline LSIL or HSIL to <LSIL Cytology
Zeier et al (2012)64 Western Cape, South Africa 2004–09 1048 33 18% ≥LSIL to <LSIL Cytology
Paramsothy et al (2009)67 4 cities, USA 1996–2000 537 34 47% during follow-up HSIL to LSIL; LSIL to ASCUS; 
ASCUS to normal
Cytology
Minkoff et al (2001)68 6 cities, USA 1994–95 741 37 1% at baseline Lower grade abnormality 
than baseline
Cytology
Massad et al (2004)70 6 cities, USA 1994–2002 202 38 22% CIN1 to normal Histology
Heard et al (2002)71 Paris, France 1993–99 168 33 56% through follow-up Reversion to normal or from 
high to low grade
Cytology
Del Mistro et al (2004)72 Vicenza and Padova, Italy 1994–2002 201 33 37% Normal or lower SIL grade at 
subsequent exam
Cytology
Invasive cervical cancer incidence
Clifford et al (2016)63 5 cities, Switzerland 1995–2013 80 NR 54% <CIN2 to ICC Unclear
Chen et al (2014)73 Taiwan 2000–08 1360 32 28% Incidence of CIS or ICC Unclear
Guiguet et al (2009)74 62 French university 
hospitals, France
1998–2006 14 406 39 (35–44) 17% Incidence of ICC ICD10
SIL diagnosed by cytology or CIN diagnosed by histology. Detailed description of studies in appendix (pp 2–5). HPV=human papillomavirus. HSIL=high-grade squamous intraepithelial lesion. CIN=cervical 
intraepithelial neoplasia. ASCUS=atypical squamous cells of undetermined significance. LSIL=low-grade squamous intraepithelial lesion. ARV=antiretroviral. ART=antiretroviral therapy. ASC-H=atypical 
squamous cells-cannot exclude HSIL. CIS=carcinoma in situ. NR=not reported. ICD10=International Classification of Diseases version 10. ICC=invasive cervical cancer. *Studies that included women who initiated 
ART at enrolment. †Personal communication.
Table 1: Summary of studies reporting the association of ART use with high-risk HPV, cervical lesion outcomes and invasive cervical cancer incidence
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with the two studies from Asia24,25 (1·72, 1·10–2·68; 
I²=0%, p=0·34) and three from Latin America27–29 
(crude OR 1·08, 95% CI 0·84–1·39; I²=0%, p =0·99).
The pooled estimate from four cohort studies that 
followed women before and after ART initiation13–16 
provides strong evidence of a reduced prevalence of high-
risk HPV after ART compared with before ART initiation 
(crude OR 0·80, 95% CI 0·72–0·89; aOR 0·79, 95% CI 
0·71–0·88; I²=48%, p=0·15; data not shown).
Nine studies reported the association of ART duration 
with high-risk HPV prevalence.17,19–21,23,24,28,30 Although 
high-risk HPV prevalence was similar among the 
ART-naive and short-duration users (<2 years), the 
pooled OR suggests that prevalence of high-risk HPV 
was lower among prolonged ART users (≥2 years) than 
in short-duration users and ART-naive combined (crude 
OR 0·65, 95% CI 0·55–0·77; I²=0%, p=0·92; appendix 
p 19). Among the seven studies adjusted for current and 
nadir CD4 cell count,17,19–21,24,30 the association was similar 
(aOR 0·65, 95% CI 0·55–0·78; I²=0%, p=0·91, data not 
shown).
There was no evidence to suggest publication bias 
(ie, smaller studies were not more likely to report a 
positive association; Beggs rank correlation test p=0·12 
for the crude analysis, p=0·34 for adjusted analysis).
We identified 1158 publications for the association of 
ART and any cervical lesion outcome, of which 
127 duplicates were removed and 889 excluded after 
abstract review, leaving 142 articles for full review. Finally, 
we identified 38 articles that matched the inclusion 
criteria and ten additional publications through cross-
referencing (figure 1). Data from an ongoing but 
unpublished study on association of ART with the 
prevalence of histology diagnosed HSIL-CIN2+ 
(Feng et al, 2017) was also included (data provided by Y-L 
Qiao, personal communication, appendix p 3).
13 studies17,20,32–41 reported the association of ART with the 
prevalence of cytology or histology diagnosed HSIL-CIN2+ 
among 9288 women living with HIV, of whom 5161 (56%) 
were taking ART (range across studies 16% to 79%) and 
4127 (44%) were ART-naive (table 1). One publication 
pro vided data from two countries,17 and was considered as 
two individual studies in the analysis. 12 further studies 
reported the association of ART with the prevalence of 
combined cytology diagnosed outcomes of atypical 
squamous cells of undetermined significance (or 
higher),42–48 and low-grade SIL (or higher),49 histology 
diagnosed CIN (grade 1 or higher),50,51 and abnormalities 
on visual inspection with colposcopy (appendix p 20).52,53
Ten studies reported the association of ART with 
cytology diagnosed SIL incidence,15,54–62 and two studies 
with histology diagnosed HSIL-CIN2+ incidence17,63 from 
a combined total of 5096 women (table 1). We included 
ten studies31,54,55,61,64–69 for cytology diagnosed SIL progres-
sion from a combined total of 6212 women, and 
ten studies15,31,54,61,64,67,68,70–72 for regression of histology 
diagnosed CIN or cytology diagnosed SIL from a 
combined total of 5261 women (table 1). Only one study 
reported the regression from histological CIN grade 1 to 
normal.70 Three studies63,73,74 reported the association of 
ART with invasive cervical cancer incidence among 
15 846 women. Studies reporting the association of ART 
with cervical lesion incidence, progression and regression, 
and invasive cervical cancer incidence are summarised in 
figure 3.
The pooled OR among 14 studies17,20,31–41 reporting the 
association of ART and cervical lesion prevalence 
suggests no evidence of an association of ART with the 
Crude analysis* Adjusted analysis†
n studies OR (95%CI) I² p value for 
heterogeneity
n studies OR (95%CI) I² p value for 
heterogeneity
High-risk HPV prevalence
All 20 0·82 (0·68–0·98) 71·0% <0·0001 12 0·83 (0·70–0·99) 51·0% 0·02
Africa 9 0·67 (0·52–0·88) 58·8% 0·01 6 0·70 (0·56–0·88) 0% 0·97
Asia 4 1·60 (0·93–2·75) 38·6% 0·18 2 1·72 (1·10–2·68) 0% 0·34
Latin America 3 1·08 (0·84–1·39) 0% 0·99 ·· ·· ·· ··
Europe or 
North America
4 0·75 (0·63–0·88) 29·9% 0·23 3 0·74 (0·59–0·93) 48·4% 0·14
HSIL-CIN2+ prevalence
All 14 0·92 (0·70–1·20) 56·6% 0·01 4 0·65 (0·40–1·06) 29·5% 0·25
Africa 9 0·84 (0·64–1·10) 45·5% 0·07 3 0·70 (0·48–1·01) 0% 0·40
Asia 2 0·66 (0·05–9·37) 83·7% 0·01 ·· ·· ·· ··
Latin America 1 2·31 (1·02–5·23) ·· ·· ·· ·· ·· ··
Europe or North 
America
2 0·83 (0·43–1·57) 32·2% 0·23 ·· ·· ·· ··
HPV=human papillomavirus. OR=odds ratio. HSIL-CIN2+=high-grade squamous intraepithelial lesions or cervical intraepithelial neoplasia, grade 2 or higher. 
ART=antiretroviral therapy. *Includes studies with no adjustment and studies that adjust for sociodemographic factors only but no adjustment for HIV-related factors. 
†Adjusted for at least one of the following: current CD4 cell count, nadir CD4 cell count, and ART duration.
Table 2: Meta-analysis of the association of ART with the prevalence of high-risk HPV and HSIL-CIN2+ among women living with HIV
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prevalence of HSIL-CIN2+ diagnosed by either cytology 
or histology (crude OR 0·92, 95% CI 0·70–1·20; 
I²=56·6%, p=0·01; table 2, figure 2). Restricting the 
analysis to those studies17,20,32–34,38,39 with histological 
confirmation found no evidence of an association (crude 
OR 0·99, 95% CI 0·69–1·41; I²=58·7%, p=0·01; data not 
shown) but when analyses were restricted to studies17,20 
that adjusted for both current CD4 cell count and ART 
duration, there was some evidence that ART users had 
decreased prevalence of HSIL-CIN2+ compared with 
ART-naive women (aOR 0·85, 95% CI 0·62–1·18; I²=0%, 
p=0·56, adjusted for current CD4 cell count alone; aOR 
0·65, 95% CI 0·40–1·06; I²=29·5%, p=0·25, with 
additional adjustment for duration on ART). 
Three studies,17,20 all from the African region, reported 
the association of ART duration with prevalent 
HSIL-CIN2+ diagnosed by histology. The pooled OR 
suggests that CIN2+ was lower among prolonged ART 
users (≥2 years) than in short-duration users (<2 years) 
and ART-naive combined (aOR 0·68, 0·49–0·94; 
High-risk HPV prevalence
Kelly et al (2017), Burkina Faso*
Kelly et al (2017), South Africa*
Zeier et al (2015)*
Ezechi et al (2014)
Reddy et al (2014)*
Rositch et al (2013)
De Vuyst et al (2012)*
Jaquet et al (2012)*
Veldhuijzen et al (2011)
Menezes et al (2016)
Zhang et al (2014)*
Mane et al (2012)*
Aggarwal et al (2012)
Rocha-Brischiliari et al (2014)
Dames et al (2014)
Grinsztejn et al (2009)*
Konopnicki et al (2013)*
Blitz et al (2013)
Minkoff et al (2010)*
Fife et al (2009)*
Subtotal (I2=71·0%, p<0·0001)
HSIL-CIN2 + prevalence
Kelly et al (2017), Burkina Faso*
Kelly et al (2017), South Africa*
Memiah et al (2015)
Huchko et al (2014)
De Vuyst et al (2012)*
Mabeya et al (2012)
Feng et al (2017)†
De Andrade et al (2011)
Sahasrabuddhe et al (2010)
Ezechi et al (2014)
Patrelli et al (2013)
Firnhaber et al (2010)
Mogtomo et al (2009)
Kitchener et al (2007)
Subtotal (I2=56·6%, p=0·005)
0·76 (0·47–1·22)
0·61 (0·37–1·01)
0·72 (0·39–1·32)
0·40 (0·32–0·50)
0·71 (0·30–1·67)
1·16 (0·62–2·16)
0·64 (0·40–1·02)
0·84 (0·46–1·54)
0·77 (0·38–1·59)
0·61 (0·20–1·88)
2·30 (1·09–4·85)
1·46 (0·84–2·54)
3·11 (0·87–11·13)
1·04 (0·50–2·14)
1·06 (0·41–2·70)
1·09 (0·82–1·44)
0·72 (0·41–1·27)
0·70 (0·48–1·01)
0·60 (0·44–0·81)
0·83 (0·74–0·94)
0·82 (0·68–0·98)
0·86 (0·26–2·83)
0·54 (0·32–0·91)
0·55 (0·19–1·56)
1·01 (0·79–1·30)
0·91 (0·51–1·62)
1·18 (0·56–2·49)
0·14 (0·02–1·09)
2·31 (1·02–5·23)
2·16 (1·09–4·28)
0·44 (0·19–1·01)
0·64 (0·35–1·18)
1·31 (0·92–1·86)
0·44 (0·16–1·26)
1·26 (0·51–3·11)
0·92 (0·70–1·20)
Burkina Faso
South Africa
South Africa
Nigeria
Malawi
Uganda
Kenya
Côte d'Ivoire
Rwanda
India
China
India
India
Brazil
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Brazil
Belgium
Canada
USA
US/Puerto Rico
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South Africa
Kenya
Kenya
Kenya
Kenya
China
Brazil
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Italy
South Africa
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..
 30/159
 96/253
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Figure 2: Meta-analysis of the prevalence of high-risk HPV and HSIL-CIN2+ among ART users compared with ART-naive
Weights are from random-effects analysis. HPV=human papillomavirus. HSIL=high-grade squamous intraepithelial lesion. CIN2+=cervical intraepithelial lesion, 
grade 2 or higher. ART=antiretroviral therapy. NR=not reported. *Studies that adjusted for any of ART duration, current or nadir CD4 cell count. †Personal 
communication. ‡Includes France, Ireland, Italy, Poland, and the UK ((authors report rate ratio of cytology-diagnosed HSIL+ among ART users over follow-up as 
opposed to odds ratio). 
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I²=2.5%, p=0·36, adjusted for age and current CD4 cell 
count; appendix p 19).
Study size varied widely (range 70–3185 women living 
with HIV). The largest study33 enrolled 3185 women 
(34% of participants included in the meta-analysis). 
However, excluding this study did not change the overall 
results. We found no evidence to suggest publication bias 
among studies reporting cervical lesion prevalence 
(Begg’s rank correlation test; crude analysis p=0·48, 
adjusted analysis p=0·50).
SIL-CIN incidence
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Firnhaber et al (2012)
Kreitchmann et al (2013)
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Sirera et al (2008)
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Figure 3: Meta-analysis of cervical lesion incidence, progression and regression, and invasive cervical cancer incidence among ART users compared with ART-naive
Weights are from random effects analysis. Only studies that reported HR from time-to-event analysis included in the meta-analysis (table 3). HR=hazard ratio. 
OR=odds ratio. SIL=squamous intraepithelial lesion. CIN=cervical intraepithelial neoplasia.*Adjusted for the time-varying effects of ART or CD4 cell count. 
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An additional sensitivity analysis including low-grade 
lesion outcomes (atypical squamous cells of 
undetermined significance or low-grade SIL diagnosed 
by cytology, CIN [grade 1 or higher] diagnosed by 
histology, and ab normality on visual inspection with 
colposcopy) suggests that ART is associated with a 
reduction in these outcomes, although these associations 
were not significant (appendix pp 20–22).
The pooled HR among ten studies15,54–62 reporting the 
association of ART and cervical lesion incidence provides 
weak evidence of an association of ART with 
cytology diagnosed SIL incidence (crude HR 0·75, 
95% CI 0·56–1·00; I²=41%, p =0·09; table 3). Among 
five studies that adjusted for the time-varying effects of 
ART,15,54,58,60,62 we found evidence of a reduction in SIL 
incidence among ART users (aHR 0·64, 95% CI 0·47–0·86; 
I²=19·4%, p=0·29). There was no evidence to suggest 
publication bias for these studies (Beggs rank correlation 
test; crude analysis p=0·42, adjusted analysis p=1·000).
When analyses were restricted to two studies17,63 that 
reported incidence of HSIL-CIN2+ determined by 
histology, there was strong evidence that prolonged 
duration ART users had reduced incidence compared 
with ART-naive women (aOR 0·59, 95% CI 0·40–0·87 
[adjusted for nadir CD4 cell count]; I²=0%, p=0·35, data 
not shown).
The pooled HR among six studies31,55,64–67 suggests a 
reduced hazard of cytology diagnosed SIL progression 
among ART users (crude HR 0·64, 95% CI 0·56–0·74; 
I²=0%, p=0·42; table 3). Restricting the analysis to four 
studies64–67 that adjusted for time-varying ART did not 
alter the estimate (aHR 0·64, 95% CI 0·54–0·75; 
I²=17·8%, p=0·30). Similarly, there was no variation in 
HR by region.
The pooled HR among six studies15,31,64,67,70,71 suggests an 
increased likelihood of regression of cytology diagnosed 
SIL or histology diagnosed CIN among ART users (crude 
HR 1·61, 95% CI 1·31–1·97; I²=18·3%, p=0·30; table 3). 
Restricting the analysis to five studies15,64,67,70,71 that adjusted 
for time-varying ART during follow-up did not alter the 
estimate (aHR 1·54, 95% CI 1·30–1·82; I²=0%, p=0·42). 
Although most studies reported progression or 
regression of any cytology diagnosed SIL grade, one study 
reported progression of low-grade SIL to a higher grade, 
and regression from high-grade to low-grade SIL, 
diagnosed by cytology.64 No change in the estimate was 
observed when excluding that study for either the 
progression or regression outcomes. No evidence 
suggests publication bias for the progression studies 
(Beggs rank correlation test, p=0·85), but there is some 
evidence for bias in the regression studies (p=0·04) 
because more of the small studies report a positive 
association of ART with regression. However, the largest 
study (enrolling 1048 women living with HIV followed up 
over a median 18 months64) finds a significant increased 
likelihood of regression among ART users compared 
with ART-naive participants (aHR 1·71, 95% CI 1·29–2·27, 
adjusted for ART duration, age, and excision treatment), 
suggesting a real beneficial effect of ART.
The pooled HR among two studies73,74 suggests a 
decreased risk of invasive cervical cancer incidence 
among ART users (crude HR 0·40, 95% CI 0·18–0·87; 
Crude analysis* Adjusted analysis†
n studies HR (95%CI)‡ I² p value for 
heterogeneity
n studies HR (95%CI)‡ I² p value for 
heterogeneity
SIL incidence
All 10 0·75 (0·56–1·00) 40·9% 0·09 5 0·64 (0·47–0·86) 19·4% 0·29
Africa 2 0·59 (0·44–0·80) 0% 0·71 1 0·62 (0·42–0·91) ·· ··
Latin America 1 1·90 (0·90–4·01) ·· ·· ·· ·· ·· ··
Europe or North America 7 0·73 (0·52–1·03) 14·0% 0·32 4 0·64 (0·40–1·02) 39·0% 0·18
SIL progression
All 6 0·64 (0·56–0·74) 0% 0·42 4 0·64 (0·54–0·75) 17·8% 0·30
Africa 3 0·67 (0·56–0·79) 0% 0·68 2 0·68 (0·57–0·80) 0% 0·65
Europe or North America 3 0·62 (0·43–0·90) 46·4% 0·16 2 0·57 (0·39–0·85) 58·0% 0·12
SIL-CIN regression
All 6 1·61 (1·31–1·97) 18·3% 0·30 5 1·54 (1·30–1·82) 0% 0·42
 Africa ·· ·· ·· ·· 1 1·71 (1·29–2·27) ·· ··
Europe or North America 5 1·62 (1·21–2·16) 28·4% 0·23 4 1·45 (1·17–1·81) 1·8% 0·38
Invasive cervical cancer incidence
All 2 0·40 (0·18–0·87) 32·7% 0·22 1 0·50 (0·29–0·87) ·· ··
*Includes studies with no adjustment potential confounders and studies that adjust for sociodemographic factors only but no adjustment for HIV related factors. †Includes 
studies that adjusted for time-varying ART or time-varying CD4 cell count. ‡Only studies that reported HR from time-to-event analysis included in the meta-analysis. 
HR=hazard ratio. SIL=squamous intraepithelial lesions. CIN=cervical intraepithelial neoplasia. 
Table 3: Meta-analysis of the association of ART with cervical lesion incidence, progression and regression, and invasive cervical cancer incidence among 
women living with HIV
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I²=32·7%, p=0·22; table 3). There is no evidence to 
suggest publication bias for these studies (Beggs rank 
correlation test; p=0·32, data not shown).
Discussion
Our results indicate that women on ART had a lower 
prevalence of high-risk HPV and a reduction in the 
incidence of histology diagnosed HSIL-CIN2+ and 
invasive cervical cancer, after adjustment for CD4 cell 
count and treatment duration.
To our knowledge, this is the first meta-analysis to 
investigate the associations between ART and high-risk 
HPV and cytology and histology diagnosed cervical 
lesion and invasive cervical cancer outcomes. Doing a 
meta-analysis of observational studies for high-risk HPV 
and cervical lesion outcomes has difficulties because of 
inherent differences in study populations, definitions of 
exposure and timescale of outcomes used, and the 
varying approaches to adjustment of effect estimates. 
The particular challenge with cross-sectional studies 
concerns the timing of HPV infection and development 
of cervical lesions, which might take several years, in 
relation to ART initiation and immune restoration that 
can happen more rapidly but is dependent on nadir CD4 
cell count. The discordances in natural histories of HPV, 
CIN, and HIV disease might explain the observed lack of 
effect of ART on prevalent high-grade cervical lesions in 
this analysis.
Restricting analyses to those studies that adjusted for 
nadir or current CD4 cell count or ART duration suggests 
that ART is associated with a reduction in high-risk HPV 
or cervical lesion outcomes, with less between-study 
heterogeneity. In studies that report limited or no 
association, immune reconstitution by ART might not 
have been established early enough after HPV infection 
to prevent or to reverse the development of high-risk 
HPV persistence or CIN2+. However, prospective studies 
that adjusted for the time-varying effects of ART use and 
CD4 cell count suggested a reduction in the incidence of 
CIN2+ and incidence and progression of SIL.
Several studies reported that a high nadir CD4 cell 
count was associated with a 36–70% reduced risk of high-
risk HPV29,30 and a 36–80% reduced risk of CIN2+33,39,63 
compared with those with low nadir CD4 cell count. 
Other studies17,30 have shown that, once on ART, effective 
therapy (ie, patients with prolonged duration, sustained 
HIV-1 viral suppression and stable high CD4 cell count) 
was associated with a reduction in high-risk HPV 
persistence and histology diagnosed CIN2+. Further 
evidence suggests that high-risk HPV prevalence and 
incidence decreased and cytology diagnosed SIL 
regression increased in women who were highly 
adherent to ART.15 Of crucial importance, ART is 
associated with a reduction in incidence of invasive 
cervical cancer, especially if started at higher nadir 
CD4 cell count,63 and used over longer durations by 
adherent patients.73 This encouraging finding contrasts 
with previous studies that had shown a paradoxical 
increase in invasive cervical cancer incidence after the 
introduction of highly active ART.75 This could be 
because, in the early ART era, therapy was initiated at a 
lower nadir CD4 cell count, at which full restoration of 
cervical mucosal immunity was not obtained while life 
expectancy of patients and their likelihood to develop 
cancers were higher.
The representation of studies from African settings has 
been steadily increasing; many of the earlier studies were 
done in the USA or Europe, leading to a geographical 
and period heterogeneity. The African studies17,54,55,64,65 
provide encouraging indication that earlier initiation and 
effective ART over a prolonged duration can prevent 
cervical lesion incidence and progression and promote 
regression. Conversely, we found fewer studies from 
Latin America and Asia and most were cross-sectional in 
design. These studies24–29,38,39 reported an opposite 
increased risk of high-risk HPV and high-grade cervical 
lesions among ART users. The lack of prospective studies 
in these regions prohibits a more direct assessment of 
the role of ART on longitudinal outcomes. An increased 
frequency of cervical cancer screening visits remains 
important especially among women on ART if they have 
started at a low nadir CD4 cell count. This concerns a 
generation of women who might have started ART with 
older guidelines at specific lower CD4 cell count 
thresholds and who might never have fully recovered 
their HPV-specific mucosal immune response.
We encountered several limitations in this review. 
Firstly, most cross-sectional studies used a binary 
category of ART users and treatment-naive. A more 
informative analysis would be to measure the effect of 
ART duration because there is a non-comparability 
among women initiating ART with decreasing CD4 cell 
count compared with those with higher CD4 cell count 
not yet needing treatment. Women who initiate ART are 
more likely to have advanced HIV disease, lower nadir 
CD4 cell counts, and higher HIV-1 viral loads than are 
those who have not yet started ART. The definition of 
ART-naive participants also varied across studies, which 
in some cases included women on monotherapy or dual-
therapy regimens, and we cannot rule out the possibility 
that these women could have had lower or less stable 
CD4 cell counts to justify ART initiation.
The outcome definitions for cervical lesions varied 
between studies, in particular the use of cytological and 
histological measurement and definition of progression 
and regression between grades. Most prospective studies 
used cytological outcomes instead of the more desirable 
histological endpoint and grouping of cytology diagnosed 
grades of SIL varied; this, coupled with the variation in 
ART exposure between populations (eg, varying 
regimens and duration), makes interpretation of pooled 
data less clear. The possibility of unmeasured 
confounding also exists. Additionally, many studies did 
not report on likely predictors or effect modifiers of 
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progression or regression of cervical lesions, which 
include nadir CD4 cell count, ART adherence, and HIV 
virological control. When available, we did sensitivity 
analysis that adjusted for time-varying effects of ART. 
Finally, individual patient-level data meta-analysis would 
allow for better harmonisation of these definitions and 
adjustments, which would provide a more precise and 
robust estimate of the association of ART and high-risk 
HPV and cervical lesion outcomes.
Our review has practical implications for the 
manage ment of HIV patients and cervical cancer 
control worldwide. The current recommendation of 
encouraging earlier ART initiation, coupled with rapid 
virological control, and sustained adherence is likely to 
lead to an earlier and possibly more functionally 
complete mucosal immune reconstitution. We expect 
that this should in turn lead to a more rapid clearance of 
high-risk HPV, thus reducing cytology diagnosed SIL 
and histology diagnosed CIN incidence or progression 
and ultimately reducing cervical cancer incidence in 
this high-risk population. ART users with low or 
unknown nadir CD4 cell count remain at significant 
high risk despite ART initiation and should be screened 
frequently.
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